Ironwood Pharmaceuticals | IRWD - Current Liabilities


Ironwood Pharmaceuticals reported $242.5M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 277.11M 79.47M Dec/2025
Agios Pharmaceuticals USD 82.21M 7.45M Dec/2025
Akebia Therapeutics USD 162.94M 29.56M Dec/2025
Almirall EUR 350.64M 52.12M Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Amarin USD 194.46M 12.23M Dec/2025
Ardelyx USD 88.6M 5.22M Dec/2025
Astellas Pharma JPY 1.32T 873M Dec/2025
AstraZeneca USD 30.62B 3.44B Dec/2025
Charles River Laboratories USD 1.12B 1.57M Dec/2025
Coherus Biosciences USD 140.39M 231.91M Dec/2025
Emergent BioSolutions USD 651.3M 12.7M Dec/2023
Esperion Therapeutics USD 300.81M 58.22M Dec/2025
Halozyme Therapeutics USD 177.09M 660.14M Dec/2025
Incyte USD 1.52B 176.44M Dec/2025
Ironwood Pharmaceuticals USD 242.5M 9.98M Sep/2025
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
Lexicon Pharmaceuticals USD 20.87M 853K Dec/2025
MacroGenics USD 43.11M 1.36M Dec/2025
Moderna USD 1.99B 306M Dec/2025
Myriad Genetics USD 133.8M 14.2M Dec/2025
Pacira USD 120.59M 13.51M Dec/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Sarepta Therapeutics USD 1.1B 173.86M Dec/2025
Takeda JPY 2.61T 470.53B Dec/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025